Since its discovery nearly 40 years ago, p53 has ascended to the forefront of investigated genes and proteins across diverse research disciplines and is recognized most exclusively for its role in cancer as a tumor suppressor. Levine and Oren (2009) reviewed the evolution of p53 detailing the significant discoveries of each decade since its first report in 1979. In this review, we will highlight the emerging non-canonical functions and regulation of p53 in stem cells. We will focus on general themes shared among p53's functions in non-malignant stem cells and cancer stem-like cells (CSCs) and the influence of p53 on the microenvironment and CSC niche. We will also examine p53 gain of function (GOF) roles in stemness. Mutant p53 (p53) GOFs that lead to survival, drug resistance and colonization are reviewed in the context of the acquisition of advantageous transformation processes, such as differentiation and dedifferentiation, epithelial-to-mesenchymal transition (EMT) and stem cell senescence and quiescence. Finally, we will conclude with therapeutic strategies that restore wild-type p53 (p53) function in cancer and CSCs, including RING finger E3 ligases and CSC maintenance. The mechanisms by which p53 and p53 influence stemness in non-malignant stem cells and CSCs or tumor-initiating cells (TICs) are poorly understood thus far. Further elucidation of p53's effects on stemness could lead to novel therapeutic strategies in cancer research.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187782 | PMC |
| http://dx.doi.org/10.3390/ijms17121982 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic value of multi-tumor-associated autoantibody expression in esophageal squamous cell carcinoma and correlation of clinical features.
Front Immunol
January 2025
Zhongshan City People's Hospital, Zhongshan, Guangdong, China.
Objective: This study aimed to investigate the diagnostic value of 7-tumor associated autoantibodies (7-TAAB) and to evaluate the relationship between 7-TAAB and clinical features in esophageal squamous cell carcinoma (ESCC), which can be used to guide clinical diagnosis and treatment and achieve its clinical value.
Methods: (1) Blood specimens were collected from patients with ESCC who had not previously received antitumor therapy (ESCC group) and those who had normal medical check-ups in the hospital during the same period (control group). The concentrations of 7-TAAB (P53, PGP9.
Toripalimab plus chemotherapy for metastatic muscle-invasive bladder cancer with a high tumor proportion score: a case report.
Front Immunol
January 2025
Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Background: Radical cystectomy (RC) combined with pelvic lymph node dissection (PLND) is the standard treatment for muscle-invasive bladder cancer (MIBC). For metastatic MIBC patients, platinum-based chemotherapy remains the first choice treatment. However, approximately 50% of patients with metastatic MIBC are ineligible for platinum-based adjuvant chemotherapy because of impaired renal function.
View Article and Find Full Text PDFInhibiting autophagy selectively prunes dysfunctional tumor vessels and optimizes the tumor immune microenvironment.
Theranostics
January 2025
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan Province, People's Republic of China.
Dysfunctional tumor vasculature, hypoxia, and an immunosuppressive microenvironment are significant barriers to effective cancer therapy. Autophagy, which is critical for maintaining cellular homeostasis and apoptosis resistance, is primarily triggered by hypoxia and nutrient deprivation, conditions prevalent in dysfunctional tumor vessels due to poor circulation. However, the role of autophagy in dysfunctional tumor endothelial cells and its impact on treatment and the tumor microenvironment (TME) remain poorly understood.
View Article and Find Full Text PDFPCAT19: the role in cancer pathogenesis and beyond.
Front Cell Dev Biol
December 2024
Department of General Surgery, Nanchang Third Hospital, Nanchang, Jiangxi, China.
PCAT19, a long non-coding RNA, has attracted considerable attention due to its diverse roles in various malignancies. This work compiles current research on PCAT19's involvement in cancer pathogenesis and progression. Abnormal expression of PCAT19 has been observed in various cancers, and its correlation with clinical features and prognosis positions it as a promising prognostic biomarker.
View Article and Find Full Text PDFMolecular and immunohistochemical markers in appendiceal mucinous neoplasms: A systematic review and comparative analysis with ovarian mucinous neoplasms and colorectal adenocarcinoma.
Histol Histopathol
October 2024
Department of Pathology, College of Medicine, QU Health, Qatar University, Doha, Qatar.
Introduction: Appendiceal mucinous neoplasms (AMNs) represent a rare and diagnostically challenging group of tumors. This systematic review aims to summarize the reported molecular and immunohistochemical markers (IHC) associated with AMNs and compare them with ovarian mucinous neoplasms (OMNs) and colorectal adenocarcinoma (CRC).
Methods: A comprehensive search was performed in PubMed/MEDLINE/PMC, Scopus, Embase, and Web of Science databases to identify studies looking at IHC and molecular markers in AMNs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!